International Journal of Radiation Research
نشریه پرتو پژوه
Int J Radiat Res
Basic Sciences
http://ijrr.com
79
journal79
2322-3243
2345-4229
10.61186/ijrr
en
jalali
1397
4
1
gregorian
2018
7
1
16
3
online
1
fulltext
en
Treatment outcomes of (chemo) radiotherapy for oropharyngeal cancers: influence of the use of 15 MV X-rays in radiation boost
Radiation Biology
Radiation Biology
تحقيق بديع
Original Research
<div style="text-align: justify;">Background: Using high energy X-rays (>10 MV) as a radiotherapy boost in treating oropharyngeal cancers (OPC) to reduce mandible radiation exposure may result in deterioration of disease control rates due to re-build-up of X-rays at the tumor surface. Therefore, we retrospectively compared the treatment outcomes and toxicities in OPC patients treated with radiotherapy using 15 MV and/or 4–6 MV X-rays as a boost. Materials and Methods: Between 2008 and 2014, 63 OPC patients received definitive 3-dimensional conformal radiotherapy. The median total dose was 70.2 (range, 46.8–75.6) Gy. The median follow-up period for surviving patients was 48 (range, 9–88) months. Twenty-one patients (33.3%) received a boost employing 15 MV X-ray in at least one beam during treatment, and 42 patients (66.7%) received only 4–6 MV X-rays. Local control (LC), locoregional control (LRC), disease-free survival (DFS), overall survival (OS) rates and the incidence of osteoradionecrosis (ORN) in the mandible for the two cohorts were estimated using the Kaplan-Meier method and compared using the log-rank test. Results: There were no statistically significant differences between the two cohorts in either treatment outcomes (3-year LC, 81% versus 75% [p=0.742]; 3-year LRC, 71% versus 71% [p=0.925]; 3-year DFS, 66% versus 66% [p=0.934]; 3-year OS, 65% versus 78% [p=0.321]) or incidence of grade >2 ORN in the mandible (9.5% versus 11.9% [p=0.883]). Conclusion: Employing 15 MV X-rays in a boost may provide comparable treatment outcomes to 4–6 MV X-rays. However, reduction in the incidence of ORN in the mandible was not demonstrated.</div>
Oropharyngeal cancer, osteoradionecrosis, radiotherapy.
257
267
http://ijrr.com/browse.php?a_code=A-10-1-725&slc_lang=en&sid=1
H.
Kaizu
hkaizu1980@ybb.ne.jp
7900319475328460012327
7900319475328460012327
Yes
Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan
M.
Hata
7900319475328460012328
7900319475328460012328
No
Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan
S.
Takano
7900319475328460012329
7900319475328460012329
No
Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan
T.
Kasuya
7900319475328460012330
7900319475328460012330
No
Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan
G.
Nishimura
7900319475328460012331
7900319475328460012331
No
Department of Otorhinolaryngology and Head and Neck Surgery, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
I.
Koike
7900319475328460012332
7900319475328460012332
No
Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan
T.
Taguchi
7900319475328460012333
7900319475328460012333
No
Department of Otorhinolaryngology and Head and Neck Surgery, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
N.
Oridate
7900319475328460012334
7900319475328460012334
No
Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan